Clinical Trials Logo

Kaposiform Hemangioendothelioma clinical trials

View clinical trials related to Kaposiform Hemangioendothelioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05351216 Recruiting - Clinical trials for Kaposiform Hemangioendothelioma

The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma

Start date: March 1, 2021
Phase:
Study type: Observational

To research and explore the antibody protection and immune memory after vaccination in children with KHE during sirolimus administration. To explore the feasibility (safety and efficacy) of vaccination in a timely manner during the administration of sirolimus in children with KHE. To search for back-up plans for vaccination regimens for KHE patients taking sirolimus in children who do not respond to primary vaccination.

NCT ID: NCT04921722 Recruiting - Clinical trials for Kaposiform Hemangioendothelioma

Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

Start date: October 22, 2021
Phase: Phase 4
Study type: Interventional

In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.

NCT ID: NCT04775173 Completed - Clinical trials for Kaposiform Hemangioendothelioma

Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.

Start date: February 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of Kaposiform hemangioendothelioma.

NCT ID: NCT04448873 Completed - Clinical trials for Kaposiform Hemangioendothelioma

Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma

Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

This randomized controlled trial aims to compare guided discontinuation with maintenance treatment of sirolimus in pediatric patients with KHE.

NCT ID: NCT04077515 Completed - Hemangioma Clinical Trials

Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma

Start date: May 1, 2019
Phase: Phase 4
Study type: Interventional

to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.

NCT ID: NCT03188068 Completed - Clinical trials for Kaposiform Hemangioendothelioma

Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm that occurs predominantly in infancy or early childhood. KHE has a nearly equal sex ratio. The annual incidence of KHE has been estimated at 0.071 per 100,000 children. KHE presents with intermediate-malignant and locally aggressive characteristics but without distant metastases. This pilot trial studies sirolimus versus sirolimus plus pednisolone in treating patients diagnosed with kaposiform hemangioendothelioma (KHE) and Kasabach-Merritt phenomemon (KMP) that cannot be removed by surgery. The purpose of this study is to compare the efficacy and safety of orally administered sirolimus versus sirolimus plus pednisolone in the treatment of KHE associated with KMP.

NCT ID: NCT03001180 Recruiting - Vascular Anomaly Clinical Trials

Identification of Biomarkers for Patients With Vascular Anomalies

Start date: April 2015
Phase:
Study type: Observational

The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest proposed in this study. The study will also use blood (serum and plasma) and tissue collected and stored in a tissue bank maintained by the Department of Hematology/Oncology.